Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792282 | 0.92 | RORC (0.34) | PLK1PDPK1CDK2 | |
| SCHEMBL1655969 | 0.92 | S1PR1 (0.37) | PLK1PDPK1CDK2 | |
| SCHEMBL6794903 | 0.92 | PTGIR (0.35) | PLK1PDPK1CDK2 | |
| SCHEMBL1658164 | 0.89 | PTGDR2 (0.37) | — | |
| SCHEMBL6791786 | 0.89 | PLK1 (0.32) | PLK1PDPK1CDK2 | |
| SCHEMBL6799702 | 0.89 | PTGDR2 (0.32) | PLK1PDPK1CDK2 | |
| SCHEMBL1656590 | 0.89 | GABRA1 (0.35) | PLK1GABRA1GABRB2PDPK1CDK2 | |
| SCHEMBL6791714 | 0.88 | BRAF (0.36) | PLK1PDPK1CDK2 | |
| SCHEMBL6793459 | 0.87 | PTGDR2 (0.33) | PLK1PDPK1CDK2 | |
| Trifluoroacetic Acid SCHEMBL6792875 | 0.87 | GABRA1 (0.34) | PLK1GABRA1GABRB2PDPK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | PLK1 101/4885GABRA1 3533/4885GABRB2 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.